Your browser doesn't support javascript.
loading
Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study.
Cil, Ibrahim; Kucukarda, Ahmet; Atci, Muhammed Mustafa; Secmeler, Saban; Paksoy, Nail; Ferhatoglu, Ferhat; Ak, Naziye; Ayhan, Murat; Tataroglu Ozyukseler, Deniz; Onder, Arif Hakan; Avci, Okan; Oyman, Abdilkerim; Okten, Ilker Nihat; Gulturk, Ilkay; Akagunduz, Baran; Basoglu, Tugba; Cakir, Emre; Hacibekiroglu, Ilhan; Ozcelik, Melike; Aydiner, Adnan.
Afiliação
  • Cil I; Department of Medical Oncology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
  • Kucukarda A; Department of Medical Oncology, Trakya University School of Medicine, Edirne, Turkey.
  • Atci MM; Department of Medical Oncology, Istanbul Professor Doctor Cemil Tasçioglu City Hospital, Istanbul, Turkey.
  • Secmeler S; Department of Medical Oncology, Istanbul Professor Doctor Cemil Tasçioglu City Hospital, Istanbul, Turkey.
  • Paksoy N; Department of Medical Oncology, Istanbul University Oncology Institute, Istanbul, Turkey.
  • Ferhatoglu F; Department of Medical Oncology, Istanbul University Oncology Institute, Istanbul, Turkey.
  • Ak N; Medical Oncology, Yozgat City Hospital, Yozgat, Turkey.
  • Ayhan M; Department of Medical Oncology, Istanbul Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey.
  • Tataroglu Ozyukseler D; Department of Medical Oncology, Istanbul Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey.
  • Onder AH; Department of Medical Oncology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Turkey.
  • Avci O; Department of Medical Oncology, Namik Kemal University, Tekirdag, Turkey.
  • Oyman A; Department of Medical Oncology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
  • Okten IN; Department of Medical Oncology, Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey.
  • Gulturk I; Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
  • Akagunduz B; Medical Oncology, Erzincan Binali Yildirim University, Mengücek Gazi Hospital, Erzincan, Turkey.
  • Basoglu T; Department of Medical Oncology, Marmara University Pendik Education and Research Hospital, Marmara University School of Medicine, Istanbul, Turkey.
  • Cakir E; Department of Medical Oncology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
  • Hacibekiroglu I; Department of Medical Oncology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
  • Ozcelik M; Department of Medical Oncology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
  • Aydiner A; Department of Medical Oncology, Istanbul University Oncology Institute, Istanbul, Turkey.
Tumori ; 108(1): 19-25, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34365852
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Anticorpos Monoclonais Humanizados / Ado-Trastuzumab Emtansina Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans Idioma: En Revista: Tumori Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Turquia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Anticorpos Monoclonais Humanizados / Ado-Trastuzumab Emtansina Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans Idioma: En Revista: Tumori Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Turquia